CMS Narrows Reimbursement Code for Bioretec's Absorbable Implant
Event summary
- CMS revised the HCPCS code C1741 descriptor for Bioretec's RemeOs™ Trauma Screw, effective January 1, 2026.
- The updated descriptor explicitly narrows the scope to absorbable metallic bone fixation implants.
- Bioretec's RemeOs™ Trauma Screw received TPT status under CMS's alternative pathway for Breakthrough Device Designation and FDA market authorization.
- The RemeOs™ Trauma Screw is the first and only osteopromotive absorbable metal implant approved in the U.S.
The big picture
The CMS revision underscores the growing recognition of absorbable metallic implants in orthopedic care, aligning with broader industry trends toward patient-friendly, long-term cost-effective solutions. Bioretec's ability to secure both regulatory and payor recognition positions it as a key player in the evolving orthopedic device market. The strategic anomaly here is the rare dual endorsement from both regulators and payors, which could set a precedent for future innovative medical technologies.
What we're watching
- Adoption Pace
- How the revised HCPCS code will affect the adoption rate of Bioretec's RemeOs™ Trauma Screw in U.S. hospitals.
- Reimbursement Impact
- Whether the narrowed code descriptor will influence CMS's future reimbursement decisions for similar devices.
- Competitive Positioning
- The pace at which competitors develop absorbable metallic bone fixation implants to challenge Bioretec's market position.
Related topics